RxDoctor Payments Data

Nicholas Bellicini, DO

Gastroenterology · Pittsburgh, PANPI 1104800010

Payments from drug & device makers

$18,681in general payments, 2019–2025

Across 160 payments — averaging $116.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$8K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • AbbVie$3K
  • Bristol Myers Squibb$1K
  • Johnson & Johnson$681
  • Madrigal Pharmaceuticals$205
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$4,10022%
  • Speaking & faculty fees$9,74552%
  • Travel & lodging$8224%
  • Food & beverage$3,92621%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,681 in reported general payments places this provider in the 80th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$207,243
Medicare patients
385
Services billed
5,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine52$38,512
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates403$28,127
LinzessLinaclotide41$27,005
Mesalamine ErMesalamine30$8,345
SutabSod Sulf/Pot Chloride/Mag Sulf39$6,188
Sucralfate39$5,277
Pantoprazole Sodium387$4,249
Esomeprazole Magnesium94$1,959
Omeprazole221$1,767
CholestyramineCholestyramine (With Sugar)26$1,626
Famotidine184$1,475
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine30$591
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg27$561
Lansoprazole22$488
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl24$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,162$27,00541 claims
Braintree Laboratories, Inc.Sutab$149$6,18839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →